Prognostic Value of Albuminuria and Influence of Spironolactone in Heart Failure With Preserved Ejection Fraction: The TOPCAT Trial.

被引：0
|
作者：
Selvaraj, Senthil [1 ]
Claggett, Brain [2 ]
Shah, Sanjiv [3 ]
Anand, Inder [4 ,5 ]
Rouleau, Jean [6 ]
O'Meara, Eileen [6 ]
Desai, Akshay [2 ]
Lewis, Eldrin [2 ]
Pitt, Bertram [7 ]
Sweitzer, Nancy [8 ]
Fang, James [9 ]
Solomon, Scott [2 ]
机构：
[1] Hosp Univ Penn, Cardiol, 3400 Spruce St, Philadelphia, PA 19104 USA
[2] Brigham & Womens Hosp, Cardiol, 75 Francis St, Boston, MA 02115 USA
[3] Northwestern Univ, Chicago, IL 60611 USA
[4] VA Med Ctr, Cardiol, Minneapolis, MN USA
[5] Univ Minnesota, Minneapolis, MN USA
[6] Univ Montreal, Montreal Heart Inst, Med, Montreal, PQ, Canada
[7] Univ Michigan, Cardiol, Ann Arbor, MI 48109 USA
[8] Sarver Heart Ctr, Cardiol, Tucson, AZ USA
[9] Univ Utah, Cardiol, Salt Lake City, UT USA
来源：
CIRCULATION | 2018年 / 138卷
关键词：
Heart failure; Aldosterone; Hypertension; Renal function;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A10530
引用
收藏
页数：2
相关论文
共 50 条
  • [21] The Effect of Heart Rate in Heart Failure With Preserved Ejection Fraction: Insights From the TOPCAT Trial
    Faiwiszewski, Ariel
    Alzahrani, Talal
    Solomon, Allen J.
    Panjrath, Gurusher
    CIRCULATION, 2018, 138
  • [22] The Prognostic Value of the NAFLD Fibrosis Score on Outcomes in Heart Failure With Preserved Ejection Fraction: An Analysis of the TOPCAT Study
    Kumar, Anupam A.
    Prenner, Stuart
    Prenner, Stacey
    Chirinos, Julio A.
    CIRCULATION, 2019, 140
  • [23] Risk Stratification and Efficacy of Spironolactone in Patients with Heart Failure with Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial
    Lin, Yifen
    Zhong, Xiangbin
    Liu, Menghui
    Zhang, Shaozhao
    Xiong, Zhenyu
    Huang, Yiquan
    Fan, Yongqiang
    Xu, Xingfeng
    Guo, Yue
    Li, Yuqi
    Sun, Xiuting
    Zhou, Huimin
    Yang, Daya
    Ye, Xiaomin
    Liao, Xinxue
    Zhuang, Xiaodong
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (02) : 323 - 331
  • [24] Risk Stratification and Efficacy of Spironolactone in Patients with Heart Failure with Preserved Ejection Fraction: Secondary Analysis of the TOPCAT Randomized Clinical Trial
    Yifen Lin
    Xiangbin Zhong
    Menghui Liu
    Shaozhao Zhang
    Zhenyu Xiong
    Yiquan Huang
    Yongqiang Fan
    Xingfeng Xu
    Yue Guo
    Yuqi Li
    Xiuting Sun
    Huimin Zhou
    Daya Yang
    Xiaomin Ye
    Xinxue Liao
    Xiaodong Zhuang
    Cardiovascular Drugs and Therapy, 2022, 36 : 323 - 331
  • [25] Regional Differences in Cardiac Biomarker Profile and Effect of Spironolactone in Patients With Heart Failure and Preserved Ejection Fraction Enrolled in the TOPCAT Trial
    Desai, Akshay
    de Denus, Simon
    Claggett, Brian
    Jarolim, Petr
    Anand, Inder S.
    Fang, James C.
    Moe, Gordon
    Pitt, Bertram
    Pfeffer, Marc A.
    Rouleau, Jean L.
    Solomon, Scott D.
    Sweitzer, Nancy K.
    O'Meara, Eileen
    CIRCULATION, 2016, 134
  • [26] Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT Trial
    Desai, Akshay S.
    Liu, Jiankang
    Pfeffer, Marc A.
    Claggett, Brian
    Fleg, Jerome
    Lewis, Eldrin F.
    McKinlay, Sonja
    O'Meara, Eileen
    Shah, Sanjiv J.
    Sweitzer, Nancy K.
    Solomon, Scott
    Pitt, Bertram
    JOURNAL OF CARDIAC FAILURE, 2018, 24 (05) : 313 - 320
  • [27] Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial
    Ramalho, Sergio H. R.
    Claggett, Brian L.
    Sweitzer, Nancy K.
    Fang, James C.
    Shah, Sanjiv J.
    Anand, Inder S.
    Pitt, Bertram
    Lewis, Eldrin F.
    Pfeffer, Marc A.
    Solomon, Scott D.
    Shah, Amil M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (03) : 557 - 559
  • [28] Anemia, Mortality, and Hospitalizations in Heart Failure With a Preserved Ejection Fraction (from the TOPCAT Trial)
    Gupta, Kartik
    Kalra, Rajat
    Rajapreyar, Indranee
    Joly, Joanna M.
    Pate, Mike
    Cribbs, Marc G.
    Ather, Sameer
    Prabhu, Sumanth D.
    Bajaj, Navkaranbir S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 125 (09): : 1347 - 1354
  • [29] Spironolactone in patients with heart failure and preserved ejection fraction
    Sanchez-Sanchez, C.
    Mendoza-Ruiz de Zuazu, H. F.
    Formiga, F.
    Manzano, L.
    Ceresuela, L. M.
    Carrera-Izquierdo, M.
    Gonzalez Franco, A.
    Epelde-Gonzalo, F.
    Cerqueiro-Gonzalez, J. M.
    Montero-Perez-Barquero, M.
    REVISTA CLINICA ESPANOLA, 2015, 215 (06): : 301 - 307
  • [30] Spironolactone in patients with heart failure and preserved ejection fraction
    Nunez, J.
    Nunez, E.
    Sanchis, J.
    REVISTA CLINICA ESPANOLA, 2016, 216 (02): : 111 - 111
12345